Key result
Different types of renal replacement therapy influenced the serum concentrations of arachidonic acid derivatives, including TXB2, 5-HETE, and 15-HETE in patients with chronic kidney disease.
Why the study?
Platelet activation from dialysis leads to arachidonic acid release, but whether dialysis type influences the concentration of arachidonic acid derivatives in patients with chronic kidney disease remains undefined.
Does the type of renal replacement therapy affect the concentration of arachidonic acid derivatives in patients with chronic kidney disease?
Cross-Sectional (n=147)
No
Does the type of renal replacement therapy affect the concentration of arachidonic acid derivatives in patients with chronic kidney disease?
The type of renal replacement therapy significantly affects the concentration of arachidonic acid derivatives, with peritoneal dialysis appearing to be the most favorable method regarding these inflammatory and pro-thrombotic markers.
Answers are grounded in this paper and cite their sources.
RRT type was associated with AA derivative levels in CKD; hypothesis-generating and should not yet change practice.
Background Platelet activation is an important side effect of dialysis, resulted in a subsequent release of arachidonic acid (AA) from activated platelets. AA is involved in many pathologic conditions, such as inflammation, asthma, cancer, diabetes, hypertension, and the pathogenesis of kidney disease. The aim of this study was to define whether the dialysis type affects the concentration of AA derivatives in patients with chronic kidney disease. Methods 117 patients were qualified to the study group. Based on the type of renal replacement therapy, patients were divided into the following groups: hemodialysis (HD A – before/HD B - after hemodialysis), peritoneal dialysis (PD), kidney transplant patients (TE - before/TE A – after transplantation) and conservative treatment (CT) (30; 30; 27; 30 patients, respectively). The control group consisted of 30 healthy volunteers (NK). The ELISA methods were used to measure the concentrations of TXB2, 5-HETE, 12-HETE, and 15-HETE in the blood serum. Results Renal replacement therapy significantly influences the concentration of TXB 2 (mean ± SD [ng/mL]: HD A- 34.6 ± 9; HD B- 28.3 ± 15.2; PD- 28.3 ± 15.2; CT- 34.2 ± 8.0; TE- 36.7 ± 42.9; TE A- 27.9 ± 8.8; NK– 19.6 ± 15; p = 0.010), 5-HETE (mean ± SD [ng/mL]: HD A- 284.2 ± 428.4; HD B- 304.8 ± 516.2; PD – 530.0 ± 553.3; CT- 318.7 ± 366.0; TE- 525.6 ± 358.0; TE A – 409.8 ± 377.1; NK 838.1 ± 497.8; p < 0.001) and 15-HETE (HD A—18.1 ± 8.7; HD B- 42.2 ± 14; PD – 36.3 ± 13.8; CT- 33.7 ± 14.0; TE- 19.5 ± 10.2; TE A – 34.4 ± 16.3; NK 22.2 ± 17.8; p < 0,001). There was a significant relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of TXB 2 , 12-HETE acid, and 15-HETE. Conclusions The type of renal replacement therapy significantly affects the concentration of AA derivatives. Peritoneal dialysis is the best method of dialysis, taking into account the concentration of arachidonic acid derivatives.
No takes yet. Share an insight, caveat, or question.
Cecerska‐Heryć et al. (2020) conducted a cross-sectional in Chronic kidney disease (n=147). Renal replacement therapy (Hemodialysis, Peritoneal dialysis, Kidney transplantation) vs. Conservative treatment and healthy controls was evaluated on Serum concentration of arachidonic acid derivatives (TXB2, 5-HETE, 12-HETE, 15-HETE) (p=<0.001). Different types of renal replacement therapy influenced the serum concentrations of arachidonic acid derivatives, including TXB2, 5-HETE, and 15-HETE in patients with chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: